医脉通编译撰写，未经授权请勿转载。导语新技术、新突破——低免疫（HIP）技术的出现，或为异体移植领域带来了革命性的变革。凭借这一创新技术，无需依赖免疫抑制药物或免疫保护装置的异体移植有望成为现实，也为糖尿病干细胞疗法的未来发展奠定了坚实的基础，为再生 ...

西雅图 - 市值3.7063亿美元的细胞工程公司Sana Biotechnology, Inc. (NASDAQ: SANA)宣布其应用于1型糖尿病治疗的低免疫原性 (HIP)技术在首次人体试验中取得了令人鼓舞的结果。根据 InvestingPro ...

Sana Biotechnology is developing gene and cell therapies aimed at treating a range of diseases, including autoimmune disorders and Type 1 diabetes. The company’s Hypoimmune (HIP) Platform is ...

About the Sana Biotechnology Hypoimmune (HIP) Platform Sana’s HIP platform is designed to generate cells ex vivo that can evade the patient’s immune system to enable the transplantation of ...

07, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc ... primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use ...